Skip to main content
. 2016 Oct 27;78(6):1185–1197. doi: 10.1007/s00280-016-3175-7

Table 2.

Pharmacokinetic parameters

Parameter, mean ± SD (geometric mean) [CV  %] Cohort A
(normal renal function)
25 mg/m2
n = 8		 Cohort B
(moderate renal impairment)
25 mg/m2
n = 8		 Cohort C
(severe renal impairment)
20 mg/m2
n = 4a 		25 mg/m2
n = 4b
Non-compartmental analysis
 C max, ng/mL 161 ± 57.0
(152) [35]		 241 ± 207c
(193) [86]		 135 ± 45.7
(130) [34]		 244 ± 150
(215) [62]
Individual modeling/three-compartmental analysis
 AUC, ng*h/mL 787 ± 177
(766) [23]		 1070 ± 733
(938) [68]		 928 ± 475
(829) [51]		 857 ± 263
(823) [31]
 CL, L/h 58.9 ± 14.7
(57.5) [25]		 54.1 ± 21.9
(49.1) [41]		 51.8 ± 34.4
(44.8) [66]		 63.0 ± 30.5
(58.1) [48]
 V ss, L 7730 ± 3280
(7160) [42]		 6730 ± 2970
(6170) [44]		 5810 ± 1360
(5690) [23]		 6470 ± 3790
(5680) [59]
 CL/BSA, L/h/m2 33.5 ± 9.76
(32.5) [29]		 28.9 ± 10.7
(26.5) [37]		 27.5 ± 17.1
(24.1) [62]		 31.7 ± 11.4
(30.3) [36]
 V ss/BSA, L/m2 4230 ± 1360
(4040) [32]		 3580 ± 1480
(3320) [41]		 3130 ± 730
(3060) [23]		 3380 ± 1920
(2970) [57]
 t 1/2γ3, h 122 ± 43.8
(116) [36]		 143 ± 102
(124) [71]		 133 ± 84.4
(113) [63]		 115 ± 49.8
(103) [43]

a n = 4; three patients were not included in the statistical analysis for Cycle 1 (20 mg/m2) because they were analyzed at Cycle 2 (25 mg/m2)

b n = 4; one patient was excluded from statistical analyses because the cabazitaxel dose was decreased to 15 mg/m2

c n = 7; one patient was excluded from the calculation of summary statistics because of a sampling time deviation at the end of infusion

AUC Area under the plasma concentration–time curve, CL clearance, CL/BSA clearance normalized to body surface area, C max maximum plasma concentration, CV coefficient of variation, SD standard deviation, t 1/2γ3 elimination half-life, V ss volume of distribution at steady state, V ss /BSA volume of distribution at steady state normalized to body surface area